京新药业(002020) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥960,425,636.79, representing a 10.32% increase compared to ¥870,570,379.68 in the same period last year[7] - Net profit attributable to shareholders for Q1 2023 was ¥151,198,043.53, up 10.15% from ¥137,264,079.65 in the previous year[7] - The net profit after deducting non-recurring gains and losses was ¥137,301,166.62, reflecting a 7.03% increase from ¥128,283,249.09 year-on-year[7] - Basic and diluted earnings per share for Q1 2023 were both ¥0.18, a 12.50% increase from ¥0.16 in the previous year[7] - The net profit for the first quarter of 2023 was CNY 151,748,477.91, an increase of 10.3% compared to CNY 137,868,319.80 in the same period last year[20] - Operating profit reached CNY 174,895,031.53, up from CNY 155,172,110.78, reflecting a growth of 12.5% year-over-year[20] - The total comprehensive income for the period was CNY 151,899,910.63, compared to CNY 138,090,753.91, reflecting a growth of 10.5%[20] Cash Flow - The net cash flow from operating activities for Q1 2023 was ¥198,885,534.01, an increase of 17.49% compared to ¥169,274,493.96 in the same period last year[7] - Cash flow from operating activities was CNY 960,499,528.42, significantly higher than CNY 819,919,186.12 in the previous year, indicating a growth of 17.1%[20] - The net cash inflow from operating activities was CNY 198,885,534.01, an increase from CNY 169,274,493.96 in the previous period, representing a growth of 17.5%[21] - The total cash inflow from investment activities was CNY 414,721,912.54, compared to CNY 458,586,902.49 in the previous period, showing a decrease of 9.5%[21] - The net cash outflow from investment activities was CNY -257,496,231.46, worsening from CNY -177,508,796.25, indicating a decline of 45.06%[28] - The net cash outflow from financing activities was CNY -16,034,763.82, a significant decrease from CNY 884,532.86, reflecting a decline of 1912.79%[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥7,554,114,668.34, a 2.60% increase from ¥7,362,555,862.94 at the end of the previous year[7] - The company's non-current assets totaled CNY 4,316,212,532.94, an increase from CNY 4,081,390,078.48, showing a growth of 5.8%[20] - The total liabilities increased to CNY 1,862,260,191.83, compared to CNY 1,815,386,168.87, indicating a rise of 2.6%[20] - The total liabilities rose to ¥2,230,250,203.54 from ¥2,190,585,660.02, representing an increase of 1.8%[35] - The total current assets decreased to CNY 3,237,902,135.40 from CNY 3,281,165,784.46, reflecting a decline of 1.32%[33] - The inventory decreased to CNY 759,947,925.00 from CNY 773,699,559.82, indicating a reduction of 1.77%[33] Shareholder Equity - Shareholders' equity attributable to the parent company was ¥5,297,451,911.83, up 2.94% from ¥5,146,123,375.50 at the end of the previous year[7] - Total equity attributable to shareholders reached ¥5,297,451,911.83, up from ¥5,146,123,375.50, marking a growth of 2.9%[35] Government Support and Other Income - The company received government subsidies amounting to ¥12,519,639.92 during the reporting period[9] - Other income increased to ¥12,519,639.92 from ¥5,109,676.74, indicating enhanced revenue streams[35] Research and Development - Research and development expenses were ¥80,838,157.33, slightly higher than ¥79,224,664.20 from the previous period, indicating a focus on innovation[35] Financial Performance Metrics - The weighted average return on equity for Q1 2023 was 2.90%, an increase of 0.05 percentage points from 2.85% in the previous year[7] - The company's receivables financing increased by 169.41% to CNY 94,671,788.87 from CNY 35,140,735.52[28] - The construction in progress rose by 37.86% to CNY 392,776,786.14 from CNY 284,910,001.25, primarily due to increased project activities[28] - The fair value gains increased significantly by 3496.10% to CNY 596,602.74 from CNY 16,590.27, attributed to higher financial product returns[28] - The company reported a financial income of ¥6,243,887.32, a significant improvement compared to a financial expense of ¥14,113,355.55 in the previous period[35]